Janus Henderson Group’s Acceleron Pharma XLRN Stock Holding History

Janus Henderson Group’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,593,352	Closed	-$274M	–	2631
2021 Q3	$274M	Sell	1,593,352 -208,470	-12%	-$27.3M	0.12%	189
2021 Q2	$226M	Sell	1,801,822 -71,980	-4%	-$9.08M	0.1%	217
2021 Q1	$254M	Buy	1,873,802 +59,761	+3%	+$7.72M	0.12%	192
2020 Q4	$232M	Buy	1,814,041 +30,102	+2%	+$3.53M	0.11%	196
2020 Q3	$201M	Buy	+1,783,939	New	+$178M	0.1%	198
2020 Q1	–	Sell	-1,133,861	Closed	-$60.1M	–	1460
2019 Q4	$60.1M	Sell	1,133,861 -211,544	-16%	-$9.65M	0.03%	528
2019 Q3	$53.2M	Buy	1,345,405 +35,736	+3%	+$1.55M	0.03%	560
2019 Q2	$53.8M	Sell	1,309,669 -864	-0.1%	-$35.8K	0.03%	554
2019 Q1	$61M	Buy	1,310,533 +34,346	+3%	+$1.51M	0.03%	530
2018 Q4	$55.6M	Sell	1,276,187 -118,069	-8%	-$5.9M	0.04%	507
2018 Q3	$79.8M	Buy	1,394,256 +161,049	+13%	+$7.91M	0.04%	460
2018 Q2	$59.8M	Buy	+1,233,207	New	+$44.9M	0.03%	500

Janus Henderson Group's XLRN Position: Q4 2021 in Review

Janus Henderson Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,593,352 shares — an estimated $274M sold.

Janus Henderson Group first reported a position in XLRN in Q2 2018 and held it in 12 quarters. The position peaked at $274M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Janus Henderson Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Janus Henderson Group sold 1,593,352 Acceleron Pharma shares in Q4 2021, an estimated $274M.
Janus Henderson Group first reported a position in Acceleron Pharma in Q2 2018 and held it in 12 quarters.
Janus Henderson Group's Acceleron Pharma position peaked at $274M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Janus Henderson Group's 13F filing for Q4 2021, filed 14 Feb 2022.